Nephrogenic Systemic Fibrosis (NSF) is a rare and serious condition that affects the skin, muscles, and internal organs. It primarily occurs in individuals with impaired kidney function, particularly those on dialysis. NSF is characterized by the excessive production of collagen, a protein that forms connective tissue in the body.
The exact cause of NSF is not fully understood, but it has been linked to the use of gadolinium-based contrast agents (GBCAs) during magnetic resonance imaging (MRI) scans. GBCAs are commonly used to enhance the visibility of certain tissues during imaging procedures.
Signs and symptoms of NSF may include thickening and hardening of the skin, joint stiffness, muscle weakness, and internal organ involvement. The condition can be debilitating and may lead to significant disability.
There is currently no cure for NSF, and treatment focuses on managing symptoms and preventing further progression. Avoiding the use of GBCAs in individuals with kidney dysfunction is crucial in preventing the development of NSF.
It is important to consult a healthcare professional for proper diagnosis and management of NSF.